NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...
Combinations of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) are the accepted ...
After visiting his GP, he was referred to hospital for further testing, where he said he had to push for “progress and ...
Vietnam Investment Review on MSN
China fast-tracks Gotistobart as breakthrough cancer drug
Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.
A chef diagnosed with an aggressive form of breast cancer is now urging all men to regularly check their chests. Mat Kelly, ...
The Nubeqa (darolutamide) regimen can be used to treat adult patients with advanced HSPC if docetaxel, a chemotherapy agent, ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback